A novel class of oral, non-immunosuppressive, beta cell-targeting, TXNIP-inhibiting T1D drugs is emerging

Diabetes treatment options have improved dramatically over the last 100 years, however, close to 2 million individuals in the U.S. alone live with type 1 diabetes (T1D) and are still dependent on multiple daily insulin injections and/or continuous insulin infusion with a pump to stay alive and no or...

Full description

Bibliographic Details

Published in:	Frontiers in Endocrinology
Main Authors:	Gu Jing, SeongHo Jo, Anath Shalev
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-10-01
Subjects:	TXNIP TIX100 verapamil islets diabetes oral medication
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1476444/full